Trial · NCT00667589
Sorafenib-induced Hand- Foot Skin Reaction Treatment
NCT00667589, Phase 2, Terminated, Northwestern University; results first posted 2013-05-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sorafenib-induced Hand- Foot Skin Reaction Treatment. Trials, record NCT00667589. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00667589
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sorafenib-induced Hand- Foot Skin Reaction Treatment
- NCT number
- NCT00667589
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Northwestern University
- Conditions
- Hand-foot Skin Reaction, Rash
- Interventions
- urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (Udderly smooth® Udder Cream)
- First posted
- 2008-04-28
- Last updated
- 2013-06-05
- Results first posted
- 2013-05-27
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Skindex-16 Total Score Between Baseline and 8 Weeks | baseline and 8 weeks | The Skindex-16 questionnaire contains 16 questions related to quality of life in patients with skin disease. Total scores may range from 0 to 96, where 0 is associated with a better quality of life and 96 is associated with a worse quality of life. The data provided below indicates the change in the Skindex-16 total score between baseline and at 8 weeks. |
| Secondary | Change in Skindex-16 Total Score Between Baseline and 2 Weeks | baseline and 2 weeks | The Skindex-16 questionnaire contains 16 questions related to quality of life in patients with skin disease. Total scores may range from 0 to 96, where 0 is associated with a better quality of life and 96 is associated with a worse quality of life. The data provided below indicates the change in the Skindex-16 total score between baseline and at 2 weeks. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Skindex-16 Total Score Between Baseline and 8 Weeks | baseline and 8 weeks | Results for subjects from the fluocinonide 0.05% cream arm, subjects from the Tazarotene 0.1% cream arm, and one subject from the Urea 40% cream arm are not included in analysis because these subjects did not complete a Skindex-16 questionnaire at 8 weeks. No subjects were randomized to the Udderly Smooth Emollient arm. | units on a scale | NUMBER |
| SECONDARY | Change in Skindex-16 Total Score Between Baseline and 2 Weeks | baseline and 2 weeks | Results for one subject from the Tazarotene 0.1% cream arm and one subject from the Urea 40% cream arm are not included in analysis because these subjects did not completed a Skindex-16 questionnaire at 2 weeks. No subjects were randomized to the Udderly Smooth Emollient arm. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Skindex-16 Total Score Between Baseline and 8 Weeks | Urea 40% Cream | -20 | units on a scale | ||
| Change in Skindex-16 Total Score Between Baseline and 2 Weeks | Fluocinonide 0.05% Cream | 36 | units on a scale | ||
| Change in Skindex-16 Total Score Between Baseline and 2 Weeks | Tazarotene 0.1% Cream | -9.5 | Standard Deviation 12.0 | units on a scale | |
| Change in Skindex-16 Total Score Between Baseline and 2 Weeks | Urea 40% Cream | 1 | units on a scale |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Fluocinonide 0.05% Cream | 1 | |
| Overall Study | STARTED | Udderly Smooth® Emollient | 0 | |
| Overall Study | STARTED | Tazarotene 0.1% Cream | 3 | |
| Overall Study | STARTED | Urea 40% Cream | 2 | |
| Overall Study | COMPLETED | Fluocinonide 0.05% Cream | 0 | |
| Overall Study | COMPLETED | Udderly Smooth® Emollient | 0 | |
| Overall Study | COMPLETED | Tazarotene 0.1% Cream | 0 | |
| Overall Study | COMPLETED | Urea 40% Cream | 1 | |
| Overall Study | NOT COMPLETED | Fluocinonide 0.05% Cream | 1 | |
| Overall Study | NOT COMPLETED | Udderly Smooth® Emollient | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Fluocinonide 0.05% Cream | ||
| Total, all-cause mortality | Udderly Smooth® Emollient | ||
| Total, all-cause mortality | Tazarotene 0.1% Cream | ||
| Total, all-cause mortality | Urea 40% Cream | ||
| Total, other adverse events | Fluocinonide 0.05% Cream | 0 | 1 |
| Total, other adverse events | Udderly Smooth® Emollient | 0 | 0 |
| Total, other adverse events | Tazarotene 0.1% Cream | 0 | 3 |
| Total, other adverse events | Urea 40% Cream | 0 | 2 |
| Total, serious adverse events | Fluocinonide 0.05% Cream | 0 | 1 |
| Total, serious adverse events | Udderly Smooth® Emollient | 0 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00667589
GET https://conductscience.org/api/trials/v1/NCT00667589/registered